ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 1035 • ACR Convergence 2025

    Demographic and Clinical Correlates of 30 day Re-admission or Death During Admission in Patients With Rheumatologic Conditions : A Retrospective Cohort Analysis in a Single Academic Center

    Waleed Ali1 and Deepali Sen2, 1Wash U/BJH, St. Louis, MO, 2Washington University in St Louis, Chesterfield, MO

    Background/Purpose: Rheumatology consults are often obtained in hospitalized patients with known or suspected rheumatologic disease. Identifying factors linked to poor short-term outcomes may improve risk…
  • Abstract Number: 0769 • ACR Convergence 2025

    Increased Gait Variability at Preferred Walking Speeds is Associated with Increased Physical Activity Measures in People with Knee Osteoarthritis

    Ogundoyin Ogundiran, Steven Garcia, Joy Itodo, Oiza Peters and Kharma Foucher, UNIVERSITY OF ILLINOIS, CHICAGO, Chicago, IL

    Background/Purpose: People with knee osteoarthritis (OA) often exhibit reduced physical activity levels and increased fall risk. Gait variability, specifically center of mass (COM) variability is…
  • Abstract Number: 0385 • ACR Convergence 2025

    Musculoskeletal Ultrasound Enhances Patient Insight and Clinical Decisions: A Multi-Center Study

    Simran Nimal1, Meridith Balbach2, Aslam Fawad1, Midori Nishio3 and Erin Chew2, 1Mayo Clinic Arizona, Scottsdale, AZ, 2Vanderbilt University, Nashville, TN, 3John Muir Specialty Medical Group, Lafayette, CA

    Background/Purpose: Musculoskeletal ultrasound (MSKUS) is a valuable tool for early detection and management of inflammatory arthritis.(1) Although integrated into rheumatology guidelines, training programs, and classification…
  • Abstract Number: 0149 • ACR Convergence 2025

    Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis

    Viengneesee Thao, Molly Moore Jeffery, Nafisseh Warner and Elena myasoedova, Mayo Clinic, Rochester, MN

    Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…
  • Abstract Number: 2420 • ACR Convergence 2025

    In-patient Outcomes of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome in SLE: US National Inpatient Database (2021-2022)

    Nattanicha Chaisrimaneepan1, Pitchaporn Yingchoncharoen2 and Miriam Paz2, 1Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, 2Texas Tech University Health Sciences Center, Lubbock

    Background/Purpose: Systemic lupus erythematosus (SLE is an autoimmune disease that attacks different organs. There have been reports of hyperglycemic hyperosmolar syndrome (HHS) from steroid use…
  • Abstract Number: 2302 • ACR Convergence 2025

    Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease

    Thomas Grader-Beck1, Jennifer Reed2, Priya Patel3, Ji Soo Kim4 and Alan Baer5, 1Johns Hopkins, Reisterstown, MD, 2Johns Hopkins, Freeland, MD, 3Johns Hopkins, Annville, PA, 4Johns Hopkins, Baltimore, MD, 5Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Patient-reported outcomes (PROs) measure a patient’s health-related quality of life. The role of ESSPRI and PROMIS measures in identifying subsets of patients with Sjogren’s…
  • Abstract Number: 2003 • ACR Convergence 2025

    Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data

    Julia Buchfuhrer1, Niranjan Kathe2, Elizabeth Ibiloye3, Seth Kuranz4, Virginia Noxon-Wood4, Alexis Woods5 and Laurence Gozalo4, 1JB Arthritis and Rheumatology Center, Downey, CA, 2Amgen Inc, San Diego, CA, 3Amgen Inc, Thousand Oaks, CA, 4Inovalon, Bowie, MD, 5Amgen, Detroit, MI

    Background/Purpose: Among patients (pts) with chronic refractory gout (CRG), traditional urate lowering therapies are often inadequate, necessitating advanced therapies. Pegloticase, a recombinant uricase enzyme, rapidly…
  • Abstract Number: 1531 • ACR Convergence 2025

    Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials

    Ioannis Parodis1, Julius Lindblom2, Roger A. Levy3, Alexander Tsoi1, Margherita Zen4, Dionysis Nikolopoulos5, Munther Khamashta6, Ryan Tomlinson7, Anca Askanase8, Ronald van Vollenhoven9 and Mandana Nikpour10, 1Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, 4University of Padua, Department of Medicine, Division of Rheumatology, Padua, Italy, 5Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 6GSK, Medical Affairs, Dubai, United Arab Emirates, 7GSK, Development – R&D, Collegeville, PA, 8Columbia University Medical Center, New York, NY, 9Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, 10University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia

    Background/Purpose: An integrated post hoc analysis of five Phase 3 trials in adults with SLE showed greater benefit of belimumab (BEL) than placebo (PBO), plus…
  • Abstract Number: 1291 • ACR Convergence 2025

    Gastrointestinal Tract Involvement in Juvenile Systemic Sclerosis: Results from an International Scoping Review of Outcome Measures

    Lauren Robinson1, Lusine Ambartsumyan2, Emily Willis3, Aybuke Gunalp4, Simone Appenzeller5, Ozgur Kasapcopur6, Sarah Ishaq7, Natalia Vasquez Canizares8 and Suzanne Li9, 1Hospital for Special Surgery, New York, NY, 2Seattle Children's Hospital, Seattle, WA, 3Royal Manchester Children's Hospital, Manchester, United Kingdom, 4Cerrahpasa Medicine School, Cerrahpasa, Istanbul, Turkey, 5Unicamp, Campinas, São Paulo, Brazil, 6Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, 7Osteopathic Medicine , Touro College of Osteopathic Medicine, New York, NY, 8Children's Hospital at Montefiore, New York, NY, 9Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ

    Background/Purpose: Gastrointestinal (GI) tract involvement is nearly universal in patients with systemic sclerosis (SSc) leading to significant morbidity and mortality. In a North American juvenile…
  • Abstract Number: 1031 • ACR Convergence 2025

    Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021

    Satani Sharkas1, Dina Murad2 and Dariush Jahandideh3, 1Boston Medical Center - Brighton, Brighton, MA, 2Tufts Medical Center, Boston, MA, 3Boston Medical Center - Brighton, Boston

    Background/Purpose: Rheumatoid arthritis (RA) is a growing public health concern in the United States, with increasing prevalence and disease burden over recent decades. This study…
  • Abstract Number: 0748 • ACR Convergence 2025

    Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis?

    Iztok HOLC1, Metka Koren Krajnc2, Marko Gačnik3 and Anja Lah4, 1University Medical Center Maribor, 2000 Maribor, Slovenia, 2University Medical center, Maribor, Slovenia, 3University Medical Center Maribor, Braslovče, Slovenia, 4University Medical Center Maribor, Laporje, Slovenia

    Background/Purpose: Giant cell arteritis (GCA) is a chronic vasculitis where relapses frequently occur. The rates of relapses of GCA have not been defined by now.We…
  • Abstract Number: 0376 • ACR Convergence 2025

    An Internet-Delivered, Arthritis-Tailored Cognitive Behavioral Therapy for Insomnia Program for People with Co-Morbid Sleep Disturbance: Comparing Baseline Characteristics of Cannabis Users and Non-Users

    Nicole Andersen1, Diane Lacaille2, Josee Savard3, Elham Rahme1, Paul Fortin4 and Deborah Da Costa5, 1McGill University, Montreal, QC, Canada, 2Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 3Université Laval, Quebec, Canada, 4Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 5McGill University, Pointe-Claire, QC, Canada

    Background/Purpose: The use of cannabis among individuals with rheumatologic conditions has gained increasing attention due to potential effects on pain, mood, and overall quality of…
  • Abstract Number: 2393 • ACR Convergence 2025

    Improving Clinical Outcomes In SLE Arthritis Trials: Post-Hoc Analysis Of A Prospective Intervention Study

    Samuel Wood1, Khaled Mahmoud2, Md Yuzaiful Md Yusof2, Philip Conaghan2, Elizabeth Hensor2 and Ed Vital3, 1University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3University of Leeds, Leeds, England, United Kingdom

    Background/Purpose: Musculoskeletal (MSK) manifestations of SLE are the most frequently assessed domain in clinical trials. Optimal MSK assessment is contested; candidates include the binary or…
  • Abstract Number: 2282 • ACR Convergence 2025

    Effect of Online Continuing Education on Advancing Care for Rheumatoid Arthritis: A Real-World Outcome Analysis

    Nimish Mehta1, Katie Lucero2, Freddy Green3 and Karen Badal4, 1Medscape, Three Bridges, NJ, 2Medscape, Newark, 3Medscape, London, United Kingdom, 4Medscape, New York, NY

    Background/Purpose: In recent years, an increasing number of cytokines and their function in the pathophysiology of immunologic conditions have been identified, leading to the development…
  • Abstract Number: 1983 • ACR Convergence 2025

    Documenting Transition: A Review and Intervention to Increase the Receipt of Transition Summary Letters

    Kyla Blasingame1, David McDonald1, Karissa Chesky1, Jimin Kim1, charles lee1, Tiphanie Vogel1 and Miriah Gillispie-Taylor2, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine/Texas Children's Hospital, Houston, TX

    Background/Purpose: The transition from pediatric to adult care poses unique challenges for patients with childhood-onset disease, many of whom were young at presentation and do…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 59
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology